Show simple item record

dc.contributor.authorYokoyama, Yujiro
dc.contributor.authorBriasoulis, Alexandros
dc.contributor.authorTakagi, Hisato
dc.contributor.authorKuno, Toshiki
dc.description.abstractSeveral randomized controlled trials (RCTs) were conducted to investigate the effect of remdesivir for patients with COVID-19, but their results were conflicting. Thus, we conducted a network meta-analysis comparing the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care. Our network meta-analysis of 4 randomized controlled trials demonstrated that the rate of clinical improvement was significantly higher in the 5-day remdesivir group and 10-day remdesivir group compared to standard care group (OR [95% confidence interval [CI]] =1.89 [1.40-2.56], P <0.001, OR [95% CI] =1.38 [1.15-1.66], P <0.001, respectively). In addition, the rate of clinical improvement was significantly higher in the 5-day remdesivir group compared to the 10-day remdesivir group (OR [95% confidence interval [CI]] =1.37 [1.01-1.85], P =0.041). Our analysis demonstrated that the use of remdesivir for patients with COVID-19 was associated with the significantly higher clinical improvement rate compared with standard care alone.en_US
dc.subjectDrug Therapyen_US
dc.subjectAntiviral Agentsen_US
dc.titleEffect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trialsen_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalVirus Researchen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record